Table 1 Recommended therapy management after index event
From: Evaluation of therapy management and outcome in Takotsubo syndrome
Study population n = 72 | |
|---|---|
Therapy recommendation | |
ASA | 59 (81.9%) |
Clopidogrel | 28 (38.8%) |
Prasugrel | 2 (2.8%) |
Ticagrelor | 4 (5.6%) |
OAC | 12 (16.6%) |
LWMH once per day | 1 (1.4%) |
Statin | 47 (65.3%) |
Beta-blocker | 63 (87.5%) |
ACE inhibitor/AT inhibitor | 63 (87.5%) |
Mineralocorticoid receptor antagonist | 31 (43.1%) |
Duration of antithrombotic therapy | |
No recommendation | 41 (56.9%) |
With recommendation: | 29 (40.3%) |
1 month | 4 (5.6%) |
3 months | 8 (11.1%) |
6 months | 6 (8.3%) |
12 months | 11 (15.3%) |
Reason for OAC | |
Atrial fibrillation | 10 (13.8%) |
Heart failure | 1 (1.4%) |
Deep vein thrombosis | 1 (1.4%) |